Filing Details

Accession Number:
0000711377-10-000028
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-10-07 07:32:41
Reporting Period:
2010-10-05
Filing Date:
2010-10-07
Accepted Time:
2010-10-07 07:32:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
711377 Neogen Corp NEOG In Vitro & In Vivo Diagnostic Substances (2835) 382367843
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1189021 Edward Bradley Vice President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-10-05 503 $13.55 110,023 No 4 M Direct
Common Stock Disposition 2010-10-05 503 $34.05 109,520 No 4 S Direct
Commmon Stock Acquisiton 2010-10-05 5,391 $18.19 114,911 No 4 M Direct
Common Stock Disposition 2010-10-05 5,391 $34.05 109,520 No 4 S Direct
Common Stock Acquisiton 2010-10-06 328 $18.19 109,848 No 4 M Direct
Common Stock Disposition 2010-10-06 328 $34.05 109,520 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Option (Right to buy) Disposition 2010-10-05 503 $0.00 503 $13.55
Common Stock Common Stock Option (Right to buy) Disposition 2010-10-05 5,391 $0.00 5,391 $18.19
Common Stock Common Stock Option (Right to buy) Disposition 2010-10-06 328 $0.00 328 $18.19
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
87,835 2012-08-09 No 4 M Direct
82,444 2013-08-15 No 4 M Direct
82,116 2013-08-15 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 14,012 Indirect Held in Neogen Corportion 401-K Plan
Footnotes
  1. The options were granted 8/9/07 as NQ options and became exercisable 20% yearly thereafter
  2. The options were granted 8/15/08 as NQ options and became exercisable 20% yearly thereafter.